InterveXion Announces Positive Data in Phase 2 Study of Devextinetug in Patients with METH Overdose
Devextinetug safe and well-tolerated in patients presenting with methamphetamine overdose, and normalized agitation without producing...
top of page
InterveXion Therapeutics, LLC
InterveXion Therapeutics
Developing a comprehensive program of therapies for people with methamphetamine use disorder
"Methamphetamine is a synthetic stimulant that is addictive and can cause considerable health adversities that can sometimes result in death."
- SAMHSA.gov/meth
About InterveXion Therapeutics, LLC
Privately held clinical-stage biotech company focused on treating methamphetamine use disorder
InterveXion is developing a comprehensive program of therapies to treat people with methamphetamine use disorder, including both short and long-acting monoclonal antibodies and vaccines. These antibodies work by binding methamphetamine and preventing its entry into the CNS.
InterveXion has been fully funded to date by National Institute on Drug Abuse (NIDA) grants. Our lead product, devextinetug (also called IXT-m200), is in Phase 2 clinical development for both treatment of methamphetamine use disorder and methamphetamine overdose. InterveXion has received Fast Track designation from the FDA and we have positive Phase 2 POC data in people who use methamphetamine.
Follow-on programs for methamphetamine use disorder include a vaccine and long-acting monoclonal antibodies against methamphetamine both with reduced dose frequency.
For more on InterveXion, please watch the video below.
Our Team
Keith Ward, PhD
Chief Executive Officer
Mike Owens, PhD
Chief Scientific Officer
Misty Stevens, PhD, MBA
Chief Operating Officer
Ralph Henry, PhD
VP Biopharmaceutics
W. Brooks Gentry, MD
Chief Medical Officer
bottom of page